|
000
| 01071nam 2200253za 4500 |
|---|
| 001 | 9.688899 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20210624231639 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 150407|2007||||xxc|||||o f|0| 0 eng d |
|---|
| 020 | |a0-662-44224-5 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-33/2007E-PDF |
|---|
| 110 | 1 |aCanada. |bHealth Products and Food Branch. |
|---|
| 245 | 10|aDraft guidance document for industry : |h[electronic resource]|breporting adverse reactions to marketed health products |
|---|
| 250 | |aDRAFT 2006-09-15 |
|---|
| 260 | |aOttawa - Ontario : |bHealth Canada. |cc2006. |
|---|
| 300 | |a44p.|breferences, tables |
|---|
| 590 | |a08-26|b2008-06-27 |
|---|
| 690 | 07|aHealth care products|2gcpds |
|---|
| 775 | 08|tÉbauche du document de lignes directrices à l'intention de l'industrie : |w(CaOODSP)9.633319 |
|---|
| 794 | |tGuidance document for industry - reporting adverse reactions to marketed health products |w(CaOODSP)9.692198 |
|---|
| 856 | 40|ahttp://publications.gc.ca|qPDF|s157 Kb|uhttps://publications.gc.ca/collections/collection_2008/hc-sc/H164-33-2007E.pdf |
|---|